Establishment of cancer surveillance using serum anti-p53 antibody in patients with ulcerative colitis

点击翻译按钮获取中文摘要

Here we evaluated clinical usefulness of the measurement of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples from ulcerative colitis (UC) patients. Serum p53 Ab was positive in 15.0% of UC, while it was positive only in 1.6% of HCs. Eight of 13 (61.5%) UC patients with CRC or dysplasia were positive for serum p53 Abs. This study revealed that p53 Ab developed in the progression of UC-associated CRC but not in all patients with neoplasia, suggesting that it is helpful in salvaging patients who drop from a surveillance program.